Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Zevra Therapeutics (ZVRA) over the last 11 years, with Q3 2025 value amounting to $392000.0.

  • Zevra Therapeutics' Depreciation & Amortization (CF) fell 7575.76% to $392000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $5.3 million, marking a year-over-year decrease of 340.09%. This contributed to the annual value of $6.4 million for FY2024, which is 53508.95% up from last year.
  • Per Zevra Therapeutics' latest filing, its Depreciation & Amortization (CF) stood at $392000.0 for Q3 2025, which was down 7575.76% from $1.7 million recorded in Q2 2025.
  • Zevra Therapeutics' Depreciation & Amortization (CF)'s 5-year high stood at $1.7 million during Q2 2025, with a 5-year trough of $62000.0 in Q3 2023.
  • Moreover, its 5-year median value for Depreciation & Amortization (CF) was $300000.0 (2022), whereas its average is $646736.8.
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first crashed by 8442.21% in 2023, then surged by 250806.45% in 2024.
  • Zevra Therapeutics' Depreciation & Amortization (CF) (Quarter) stood at $64000.0 in 2021, then soared by 368.75% to $300000.0 in 2022, then surged by 162.33% to $787000.0 in 2023, then surged by 109.4% to $1.6 million in 2024, then crashed by 76.21% to $392000.0 in 2025.
  • Its Depreciation & Amortization (CF) stands at $392000.0 for Q3 2025, versus $1.7 million for Q2 2025 and $1.6 million for Q1 2025.